Filtered By:
Vaccination: Cancer Vaccines
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 243 results found since Jan 2013.
The Use of Chimeric Antigen Receptor to Control HIV Infection
Chimeric Antigen Receptors (CARs) are engineered proteins expressed by transduction on autologous CD8 T cells; after adoptive transfer, they promote targeted killing of specific cell types. CARs are showing great promise for treating cancer. The present invention (CD4-CRD CAR) is a novel bifunctional targeting motif for an anti-HIV CAR, consisting of a region of human CD4 linked to a carbohydrate recognition domain (CRD) from one of several human C-type lectins known to interact with high-mannose glycans on HIV gp120. Compared to a “standard” CD4 CAR, the CD4-CRD CAR displays two major enhancements: 1) increased potenc...
Source: NIH OTT Licensing Opportunities - October 9, 2014 Category: Research Authors: admin Source Type: research
Vaccine pioneer begins reign as acting director of the National Cancer Institute
Dr. Douglas Lowy has been officially named acting director of the National Cancer Institute, following the March 31 exit of Dr. Harold Varmus as director. Dr. Lowy had been serving as the National Cancer Institute’s deputy director since July 2010, according to a <a...
Source: Skin and Allergy News - April 1, 2015 Category: Dermatology Tags: ONCR News ONCR Gynecologic FPN News FPN Oncology IMN Oncology SAN Clinical News SAN News PED News Source Type: news
Personalized melanoma vaccine evokes immune response
A customized vaccine targeting patient-specific, tumor neoantigens evoked an immune response in three adults with advanced cutaneous melanoma in a proof-of-principle study that paves the way for a phase I trial.
The data are “too premature to conclude that the treatment had any therapeutic benefit...
Source: Skin and Allergy News - April 2, 2015 Category: Dermatology Tags: SAN Journals SAN Clinical News SAN News SAN SCN: Melanoma ONCR Journals ONCR News ONCR Melanoma & Skin Cancers FPN Journals Source Type: news
The Use of Chimeric Antigen Receptor to Control HIV Infection
Chimeric Antigen Receptors (CARs) are engineered proteins expressed by transduction on autologous CD8 T cells; after adoptive transfer, they promote targeted killing of specific cell types. CARs are showing great promise for treating cancer. The present invention (CD4-CRD CAR) is a novel bifunctional targeting motif for an anti-HIV CAR, consisting of a region of human CD4 linked to a carbohydrate recognition domain (CRD) from one of several human C-type lectins known to interact with high-mannose glycans on HIV gp120. Compared to a “standard” CD4 CAR, the CD4-CRD CAR displays two major enhancements: 1) increased potenc...
Source: NIH OTT Licensing Opportunities - October 9, 2014 Category: Research Authors: admin Source Type: research
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.
Abstract
The ability to identify immunogenic determinants that activate T-cells is important for the development of new vaccines, allergy therapy and protein therapeutics. In silico MHC-II binding prediction algorithms are often used for T-cell epitope identification. To understand how well those programs predict immunogenicity, we computed HLA binding to peptides spanning the sequence of PE38, a fragment of an anti-cancer immunotoxin, and compared the predicted and experimentally identified T-cell epitopes. We found that the prediction for individual donors did not correlate well with the experimental data. Furth...
Source: Journal of Immunological Methods - June 6, 2015 Category: Allergy & Immunology Authors: Mazor R, Tai CH, Lee B, Pastan I Tags: J Immunol Methods Source Type: research
MPLA shows attenuated pro‐inflammatory properties and diminished capacity to activate mast cells in comparison to LPS
ConclusionsCompared to LPS, MPLA induced a qualitatively similar, but less potent pro‐inflammatory immune response, but was unable to activate human or mouse MCs.This article is protected by copyright. All rights reserved.
Source: Allergy - January 1, 2015 Category: Allergy & Immunology Authors: Stefan Schülke, Adam Flaczyk, Lothar Vogel, Nicolas Gaudenzio, Isabelle Angers, Bettina Löschner, Sonja Wolfheimer, Ingo Spreitzer, Salman Qureshi, Mindy Tsai, Stephen Galli, Stefan Vieths, Stephan Scheurer Tags: Original Article Source Type: research
Sean Parker Just Gave $600 Million To Help Solve The World's Biggest Problems
While it’s not unusual for tech billionaires to commit to philanthropic efforts these days, it would be tricky to find an analog for the approach being taken by former Facebook President Sean Parker with his newly announced foundation. That’s because Parker is aiming to bring a “go big or go home” Silicon Valley-informed approach to his San Francisco-based Parker Foundation, which has been established through a $600 million gift from the Napster cofounder and Spotify board member. The foundation will focus on three core areas where Parker thinks real progress can be made: civic engagement, global public health and ...
Source: Healthy Living - The Huffington Post - June 24, 2015 Category: Consumer Health News Source Type: news
Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome
Commentary on: Cannon CP, Blazing MA, Giugliano RP, et al., IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387–97. Context Use of statin therapy to treat dyslipidemia in patients with established coronary artery disease is the standard of care worldwide. Given the negative results of a number of trials that tested the use of adjuvant lipid-lowering therapies against a statin background, there has been great scepticism about whether or not non-statin drugs provide incremental benefit.1–3 Ezetimibe inhibits the absorption of both dietary and bili...
Source: Evidence-Based Medicine - September 24, 2015 Category: Internal Medicine Authors: Toth, P. P. Tags: Health policy, Epidemiologic studies, Genetics, Immunology (including allergy), Vaccination / immunisation, Stroke, Diet, Ischaemic heart disease, Health economics, Health service research, Lipid disorders Therapeutics/Prevention Source Type: research
T Follicular Helper (Tfh) Cells in Normal Immune Responses and in Allergic Disorders
This article is protected by copyright. All rights reserved.
Source: Allergy - March 10, 2016 Category: Allergy & Immunology Authors: Gilda Varricchi, James Harker, Francesco Borriello, Gianni Marone Hon, Stephen R. Durham, Mohamed H. Shamji Tags: Review Source Type: research
Id: 67: henoch-schonlein prpura with a negative skin biopsy
Conclusion
Although HSP patients mostly range from 4–7 years old it can still presents in adolescent age group. Non-thrombocytopenic palpable purpura with multi-organ involvement (gastrointestinal, skin and joints) should make one consider the diagnosis. skin biopsy should be taken less than 24 hrs from the presentation because in more chronic lesions, vessel damage leads to nonspecific leakage of all isotypes of immunoglobulin.
Abstract ID: 67 Figure 1
Source: Journal of Investigative Medicine - March 21, 2016 Category: Research Authors: Akbar, N., Akbar, S., Kubbara, A. Tags: Rheumatology/Immunology/Allergy Source Type: research
Cells to Society: Women's Empowerment / Nurse Scientists / Research News
This study investigates the patterns and factors associated with persistent high cotinine concentrations in a sample of urban children with asthma who had frequent emergency department visits.
Read more
...
Source: Johns Hopkins University and Health Systems Archive - June 15, 2016 Category: Nursing Source Type: news
Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.
Abstract
TH2-biased immune responses are associated with inadequate protection against some pathogens and with cancer, colitis, asthma and allergy. Since most currently used vaccine adjuvants induce a TH2-biased response, this has led to interest in developing adjuvants capable of activating TH1 immunity and modulating existing TH2 responses. Immunotherapies to shift immune responses from TH2 to TH1 have generally required prolonged immunization protocols and have not induced effective TH1 responses. We have demonstrated that nanoscale emulsions (NE), a novel mucosal adjuvant, induce robust IgA and IgG antibody re...
Source: Vaccine - June 13, 2016 Category: Allergy & Immunology Authors: Bielinska AU, O'Konek JJ, Janczak KW, Baker JR Tags: Vaccine Source Type: research
A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro.
Conclusion. Conjugation of MPLA and antigen enhanced the immune response compared to the mixture of both components. Due to the nonbiased boost of Ova-specific Th2 and Th17 responses while also inducing Th1 responses, this fusion protein may not be a suitable vaccine candidate for allergy treatment but may hold potential for the treatment of other diseases that require a strong stimulation of the host's immune system (e.g., cancer).
PMID: 27340679 [PubMed - in process]
Source: Journal of Immunology Research - June 26, 2016 Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
